Thomas Bohmfalk
Family Medicine · Georgetown, TXNPI 1083794077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,137 and has fallen 64.4% since, to $761 in 2021.
Across 263 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$900
- AstraZeneca$518
- Lilly USA, LLC$349
- AbbVie$328
- Astellas Pharma US Inc$305
- Amarin Pharma, Inc.$272
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,98198%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $900 |
| AstraZeneca | 24 | $518 |
| Lilly USA, LLC | 32 | $349 |
| AbbVie(2 entities) | 24 | $328 |
| Astellas Pharma US Inc | 15 | $305 |
| Amarin Pharma, Inc. | 17 | $272 |
| GSK | 20 | $220 |
| Esperion Therapeutics, Inc. | 8 | $167 |
| Merck | 19 | $152 |
| Abbott | 6 | $118 |
| Boehringer Ingelheim | 8 | $113 |
| Amgen | 6 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $68 |
| Biohaven Pharmaceuticals, Inc. | 3 | $60 |
| Johnson & Johnson | 4 | $47 |
| Pfizer | 3 | $45 |
| Shire North American Group Inc | 3 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $35 |
| Metuchen Pharmaceuticals | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Novartis | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Avion Pharmaceuticals | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Gilead | 1 | $12 |
| Eisai Inc. | 1 | $11 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$4,078 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Georgetown
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.